金吾财讯 | 白云山(00874)公告,分公司广州白云山医药集团白云山制药总厂收到国家药品监督管理局签发的药品补充申请批准通知书,获得脂降宁片和鼻渊片的药品补充申请批准通知书,提升药品说明书安全信息质量,有利于提升产品的市场竞争力,对当期业绩无重大影响。
公告指,脂降宁片和鼻渊片申请变更药品说明书中安全性等内容,而脂降宁片用于胸痹心痛,眩晕耳鸣,肢体麻木,高脂血症等。至于鼻渊片用于治疗慢性鼻炎及鼻窦炎。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.